🟠 Moderate Evidence
A systematic review published in The Lancet Regional Health – Western Pacific has identified significant disparities in cardiovascular disease (CVD) care delivery across Asia-Pacific health systems, highlighting gaps in access, quality, and efficiency that disproportionately affect resource-constrained countries. The analysis reveals that despite cardiovascular disease remaining the leading cause of death in the region, the infrastructure and delivery mechanisms for prevention and treatment remain inadequately developed in many settings.
Key takeaways
- Cardiovascular care delivery in Asia-Pacific shows substantial variation in access, quality, and efficiency across diverse health system contexts
- Resource-constrained countries face particular barriers to implementing evidence-based CVD prevention and treatment protocols
- Equity-focused strategies tailored to local health system capacities are needed to accelerate progress in the populous region
- Strengthening primary care capacity and reducing out-of-pocket costs emerge as critical priorities for CVD control
Study at a Glance
| Source | The Lancet Regional Health – Western Pacific |
| Study type | Systematic review of health system delivery models |
| Geographic scope | Asia-Pacific region |
| Focus | Cardiovascular care access, quality, and efficiency across diverse health systems |
| Publication year | 2026 |
CVD care system challenges across health contexts
Primary barriers to effective cardiovascular disease delivery in Asia-Pacific, by health system capacity
Source: The Lancet Regional Health – Western Pacific, 2026 | Georgian Medical Journal News
Unequal access shapes CVD outcomes across the region
The systematic review, published in The Lancet Regional Health – Western Pacific, documents substantial variation in how Asia-Pacific countries deliver cardiovascular care, with access to diagnostic tools, medications, and specialist services varying dramatically between upper-middle-income and lower-income health systems. Countries with stronger economic resources demonstrate more robust systems for cardiac imaging, interventional procedures, and secondary prevention programmes, while resource-limited settings struggle to provide basic screening and medication access.
This variation has direct clinical consequences: patients in under-resourced settings experience delayed diagnoses, limited access to guideline-recommended medications, and higher rates of preventable complications. The review emphasises that these disparities are not merely technical challenges but reflect fundamental inequities in how health systems prioritise and fund CVD services across the region.
Quality standards and monitoring remain inconsistent
A critical finding from the review is the absence of standardised quality metrics and monitoring systems for CVD care across most Asia-Pacific health systems. While high-income settings in the region maintain robust quality assurance frameworks tracking mortality, readmission rates, and adherence to clinical guidelines, many middle and lower-income countries lack systematic approaches to measuring care quality or identifying performance gaps.
This evidence gap complicates efforts to improve care. Without reliable data on what works in local contexts, policymakers struggle to allocate resources effectively or identify which interventions deliver the best health gains per dollar spent. The review calls for development of context-appropriate quality indicators that can be feasibly measured even in resource-constrained settings, moving beyond high-income country metrics that may not reflect local priorities or capacities.
Equity-focused strategies tailored to diverse health system contexts are essential for accelerating progress in cardiovascular disease control across the Asia-Pacific region.
— The Lancet Regional Health – Western Pacific, 2026
Out-of-pocket costs create barriers to CVD care and prevention
The systematic review identifies out-of-pocket healthcare expenses as a major barrier to CVD prevention and treatment across Asia-Pacific, particularly in lower-income countries where households bear substantially higher proportions of total health spending. When patients must pay directly for diagnostic tests, medications, or specialist consultations, many defer or forgo care, resulting in presentation at more advanced disease stages when interventions are both costlier and less effective.
This financial barrier is especially problematic for primary prevention efforts. Patients who cannot afford blood pressure monitoring or lipid screening cannot benefit from early identification of cardiovascular risk, meaning prevention programmes remain ineffective regardless of their clinical design. The review notes that countries with stronger health financing mechanisms—particularly those with universal health coverage (UHC) that eliminate point-of-care payments for essential CVD services—demonstrate better outcomes and more equitable access across socioeconomic groups.
Building stronger primary care capacity remains foundational
According to the Lancet analysis, health systems across Asia-Pacific that prioritise primary care capacity—including training non-physician health workers to manage uncomplicated hypertension and cardiovascular risk factor management—achieve better population-level health outcomes than those relying primarily on specialist-driven care. This is particularly relevant for countries with limited cardiologist workforces and geographic barriers to specialist access.
Systematic strengthening of primary care infrastructure for CVD—through task-sharing models, simplified treatment algorithms, and reliable supply chains for essential medications—emerges from the review as the most implementable pathway to expanding access across the region. Examples from countries successfully embedding CVD risk assessment into routine primary care demonstrate that this approach requires not only clinical training but also systems-level changes including integration of care protocols, supply chain management, and performance feedback mechanisms.
Strengthening cardiovascular care across the Asia-Pacific region will require coordinated action at multiple levels: health systems must establish reliable supply chains for medications and diagnostic equipment; policymakers must prioritise financing mechanisms that remove financial barriers to care; and clinical leaders must develop and disseminate simplified, evidence-based protocols suited to local capacities. For further reading on regional health equity strategies, see Global Health coverage and Health Policy analysis on GMJ News.
What this means
Frequently asked questions
Why does cardiovascular care access vary so much across Asia-Pacific countries?
According to The Lancet Regional Health – Western Pacific review, variation reflects differences in health financing capacity, workforce development, supply chain infrastructure, and policy priorities. Countries with stronger health financing mechanisms and investment in primary care infrastructure achieve more equitable access than those where out-of-pocket costs remain high and primary care capacity is limited.
Can lower-income countries implement cardiovascular care improvements without specialist-heavy systems?
Yes. The systematic review documents that health systems successfully expanding CVD care through task-sharing models—where nurses and non-physician health workers manage uncomplicated hypertension and conduct cardiovascular risk screening—achieve substantial population health gains. This approach is both more feasible and more equitable in resource-constrained settings than building large specialist cardiology infrastructure.
What is the relationship between universal health coverage and cardiovascular care quality?
The Lancet analysis shows that health systems with universal health coverage that eliminate point-of-care payments for essential CVD services achieve better outcomes and more equitable access than those where patients bear high out-of-pocket costs. Financing mechanisms that remove financial barriers are foundational to effective CVD prevention and treatment programmes.
Addressing cardiovascular care disparities in Asia-Pacific requires moving beyond high-income country models and building health systems suited to local capacities and resource availability. The evidence-based roadmap provided by this systematic review offers a realistic pathway for countries across the region to strengthen CVD care delivery, reduce inequity, and ultimately improve population health outcomes in one of the world’s most populous regions. Implementation of these findings—prioritising primary care investment, eliminating financial barriers through universal health coverage, and developing context-appropriate quality systems—should be central to regional and national health policy agendas.
Source: Systematic review of cardiovascular care delivery across health systems in the Asia–Pacific: a regional roadmap for strengthening cardiovascular care, The Lancet Regional Health – Western Pacific (2026)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
